Scinai Immunotherapeutics (SCNI) director reports sizable stock option positions

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. director Mark Germain reported his initial holdings of stock options in the company. He holds three option awards that together are exercisable for 11,628,400 Ordinary Shares at an exercise price of 0.0050 and 16,000,000 Ordinary Shares at an exercise price of 0.0050, both expiring on 2033-08-24, and 100,000,000 Ordinary Shares at an exercise price of 0.0004 expiring on 2035-12-22.

One option vests in a single installment on August 24, 2027, while the others vest in three equal annual installments starting August 24, 2024 and December 22, 2026, in each case conditioned on Mr. Germain’s continued service. The filing notes that the Ordinary Shares are represented by American Depositary Shares, each currently representing four thousand Ordinary Shares.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

GERMAIN MARK

(Last) (First) (Middle)

C/O SCINAI IMMUNOTHERAPEUTICS LTD.

JERUSALEM BIOPARK, 2ND FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Scinai Immunotherapeutics Ltd. [ SCNI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	08/24/2033	Ordinary shares, no par value per share ("Ordinary Shares")(2)	11,628,400	$0.005	D
Stock Option (right to buy)	(3)	08/24/2033	Ordinary Shares	16,000,000	$0.005	D
Stock Option (right to buy)	(4)	12/22/2035	Ordinary Shares	100,000,000	$0.0004	D

Explanation of Responses:

1. The option vests in one installment on August 24, 2027, subject to the Reporting Person's continued service through such date.

2. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

3. The option vests in three equal annual installments commencing August 24, 2024, subject to the Reporting Person's continued service through such dates.

4. The option vests in three equal annual installments commencing December 22, 2026, subject to the Reporting Person's continued service through such dates.

Remarks:

Exhibit 24 - Power of Attorney.

	/s/ Amir Reichman, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did Scinai Immunotherapeutics (SCNI) disclose in this Form 3 filing?

Scinai Immunotherapeutics disclosed director Mark Germain’s initial stock option holdings. The filing lists three option awards covering underlying Ordinary Shares, with specific exercise prices, expiration dates, and vesting schedules tied to his continued service with the company.

How many Scinai Immunotherapeutics (SCNI) shares are covered by Mark Germain’s options?

Mark Germain’s options cover 11,628,400 and 16,000,000 underlying Ordinary Shares at an exercise price of 0.0050, and 100,000,000 underlying Ordinary Shares at an exercise price of 0.0004, according to the reported stock option holdings and derivative position summary.

When do Mark Germain’s Scinai Immunotherapeutics (SCNI) stock options expire?

Two of Mark Germain’s stock option grants expire on 2033-08-24, and a third grant expires on 2035-12-22. These expiration dates define how long he has the right to exercise the options for the underlying Ordinary Shares.

What are the vesting terms of Mark Germain’s Scinai Immunotherapeutics (SCNI) options?

One option vests in a single installment on August 24, 2027. The other two vest in three equal annual installments starting August 24, 2024 and December 22, 2026, each subject to Mr. Germain’s continued service through the applicable vesting dates.

How are Scinai Immunotherapeutics (SCNI) Ordinary Shares represented by ADSs?

The filing states that the company’s Ordinary Shares are represented by American Depositary Shares. Each American Depositary Share currently represents four thousand Ordinary Shares, providing a depository structure for trading interests in the underlying equity.

Does this Scinai Immunotherapeutics (SCNI) Form 3 show any recent insider buying or selling?

This Form 3 presents Mark Germain’s existing stock option holdings rather than new market transactions. The transaction summary classifies the entries as holdings with unknown transaction codes and shows no buy, sell, exercise, gift, or tax-withholding activity.